Paper Details

  1. Home
  2. Paper Details

Open-label trial of immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults ≥ 50 years of age in Mexico.

Author: Enkerlin-PauwellsHermann Leo, GruberWilliam C, JuergensChristine, KalininaElena, PathiranaSudam, Ruiz PalaciosGuillermo M, Schmoele-ThomaBeate, ScottDaniel A, SundaraiyerVani, TinocoJuan Carlos, Vazquez-NarvaezJorge

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This open-label multicenter clinical trial assessed the immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine (PCV13) in adults ≥ 50 years of age not previously vaccinated with the 23-valent pneumococcal polysaccharide vaccine (PPSV23).
Paper Details　
Original Abstract of the Article :
This open-label multicenter clinical trial conducted in Mexico assessed the immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine (PCV13) in adults ≥ 50 years of age not previously vaccinated with the 23-valent pneumococcal polysaccharide vaccine (PPSV23). The PCV13 elicited a robu...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4308865/

データ提供：米国国立医学図書館（NLM）

Pneumococcal Conjugate Vaccine: A Safe and Effective Option for Adults in Mexico

Pneumococcal disease is a serious infection caused by bacteria called Streptococcus pneumoniae. This study evaluates the immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine (PCV13) in adults aged 50 years and older in Mexico. The researchers aimed to determine the vaccine's effectiveness in eliciting an immune response and assess its safety profile in this population.

PCV13: A Promising Vaccine for Adult Pneumococcal Disease Prevention

The study revealed that PCV13 was safe and immunogenic in adults aged 50 years and older in Mexico, eliciting a robust immune response. The vaccine was well tolerated, with no reported serious adverse events. This research provides evidence for the potential of PCV13 as a valuable tool for preventing pneumococcal disease in this age group. The study's findings contribute to the growing body of evidence supporting the use of PCV13 as a safe and effective vaccine for adults.

Protecting Older Adults from Pneumococcal Disease

The study's findings have important implications for public health strategies aimed at protecting older adults from pneumococcal disease. The research supports the use of PCV13 in adults aged 50 years and older, particularly those at higher risk for pneumococcal infection. This study highlights the importance of ongoing efforts to promote vaccine uptake and ensure that all individuals have access to safe and effective vaccines to protect them from preventable diseases.

Dr.Camel's Conclusion

The success of PCV13 in Mexico is like a refreshing oasis in the desert, offering protection against pneumococcal disease. This research provides valuable insights into the vaccine's effectiveness and safety in adults, demonstrating its potential to contribute to a healthier future for older adults. The findings underscore the importance of vaccination programs in protecting individuals from preventable diseases, ensuring that everyone has access to the tools they need to maintain their health and well-being.

Date :
  1. Date Completed 2015-10-15
  2. Date Revised 2022-03-17
Further Info :

Pubmed ID

25499011

DOI: Digital Object Identifier

PMC4308865

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.